OnCore Login

Return to Trial Database

HCRN-GU14-188

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status

Study Completed

Cancer Type(s)

Urothelial Carcinoma

Study Contact

Publications

Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188
  • CJ Hoimes, N Adra, MT Fleming, HZ Kaimakliotis, J Picus, ZL Smith, R Walling, EJ Trabulsi, JH Hoffman-Censits, MO Koch, C Cary, R Abouassaly, C Eitman, P Fu, G Goolamier, AC Calaway, LE Ponsky, WK Kelly
Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of HCRN GU14-188
  • HZ Kaimakliotis, N Adra, WK Kelly, EJ Trabulsi, RC Lauer, J Picus, ZL Smith, R Walling, TA Masterson, AC Calaway, MO Koch, E Sonderman, P Fu, G Goolamier, C Eitman, LE Ponsky, CJ Hoimes
Phase 1b/2 Multicenter Study of Neoadjuvant Pembrolizumab and Chemotherapy for Locally Advanced Urothelial Cancer (NCT02365766)
  • CJ Hoimes, C Albany, J Hoffman-Censits, M Fleming, E Trabulsi, J Picus, C Cary, MO Koch, R Walling, WK Kelly, JL Godwin, M Cooney, P Fu, A Nelson, K Patel, C Eitman, T Breen, A Neal, H Kaimakliotis
Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)
  • CJ Hoimes, R Abouassaly, JN Saltzman, MT Fleming, JH Hoffman-Censits, T Byrd, C Eitman, M Snyder-Willis, J O'Neill, L Wood, R Elliott, MM Cooney

Trial Locations

All sites in which the trial HCRN-GU14-188 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278